Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitul D Gandhi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Oncotargets and Therapy|March 11, 2014
Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinibMitul D Gandhi, Mark Agulnik
Leukemia & Lymphoma|April 2, 2014
Predicting benefit from imatinib: are we close?Mitul D Gandhi, Virginia G Kaklamani
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
Blood|May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventMitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Haematologica|January 25, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignanciesLinlin Xu, Mazyar Shadman, Ian W Flinn, et al.
Blood|December 2, 2024
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaHun Ju Lee, Rod Ramchandren, Judah Friedman, et al.
Blood|December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaJeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncotargets and Therapy|March 11, 2014
Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinibMitul D Gandhi, Mark Agulnik
Leukemia & Lymphoma|April 2, 2014
Predicting benefit from imatinib: are we close?Mitul D Gandhi, Virginia G Kaklamani
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
Blood|May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventMitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Haematologica|January 25, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignanciesLinlin Xu, Mazyar Shadman, Ian W Flinn, et al.
Blood|December 2, 2024
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaHun Ju Lee, Rod Ramchandren, Judah Friedman, et al.
Blood|December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaJeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
Pageof 1